{"id":33773,"date":"2025-05-21T01:21:34","date_gmt":"2025-05-20T17:21:34","guid":{"rendered":"https:\/\/flcube.com\/?p=33773"},"modified":"2025-05-21T01:21:35","modified_gmt":"2025-05-20T17:21:35","slug":"sirius-therapeutics-partners-with-crispr-therapeutics-to-develop-srsd107-for-thrombosis","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=33773","title":{"rendered":"Sirius Therapeutics Partners with CRISPR Therapeutics to Develop SRSD107 for Thrombosis"},"content":{"rendered":"\n

Sino-US biotech Sirius Therapeutics has entered into a partnership with Swiss\u2013American biotech CRISPR Therapeutics (NASDAQ: CRSP<\/a>) to develop and commercialize SRSD107, a Factor XI (FXI)-targeted Factor siRNA therapy for the treatment of thrombosis and thromboembolic diseases.<\/p>\n\n\n\n

Agreement Details<\/strong>
Under the agreement, CRISPR Therapeutics will provide Sirius Therapeutics with an upfront payment of USD 25 million in cash and USD 70 million in equity. The two companies will share development costs and profits equally. CRISPR Therapeutics will lead U.S. commercialization efforts, while Sirius retains exclusive rights in Greater China.<\/p>\n\n\n\n

SRSD107 Development<\/strong>
By targeting FXI, SRSD107 aims to reduce thrombotic events while minimizing the risk of bleeding, offering a differentiated approach compared to Factor Xa inhibitors. The drug is being developed to treat patients with atrial fibrillation, venous thromboembolism (VTE), cancer-associated thrombosis, chronic Coronary Artery Disease (CAD), chronic Peripheral Vascular Disease (PVD), end-stage renal disease requiring hemodialysis, and patients undergoing major orthopedic surgery, where bleeding risk limits existing therapies.<\/p>\n\n\n\n

Clinical Trials<\/strong>
SRSD107 has completed two Phase I clinical trials, with results demonstrating its good safety and tolerability. A Phase II study is currently being initiated to assess the drug\u2019s safety and efficacy for the prevention of VTE in patients undergoing total knee arthroplasty.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Sino-US biotech Sirius Therapeutics has entered into a partnership with Swiss\u2013American biotech CRISPR Therapeutics (NASDAQ:…<\/p>\n","protected":false},"author":1,"featured_media":33774,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[1650,1649,64,1962],"class_list":["post-33773","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-crispr-therapeutics","tag-nasdaq-crsp","tag-rnai-aso","tag-sirius-therapeutics"],"yoast_head":"\nSirius Therapeutics Partners with CRISPR Therapeutics to Develop SRSD107 for Thrombosis - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sino-US biotech Sirius Therapeutics has entered into a partnership with Swiss\u2013American biotech CRISPR Therapeutics (NASDAQ: CRSP) to develop and commercialize SRSD107, a Factor XI (FXI)-targeted Factor siRNA therapy for the treatment of thrombosis and thromboembolic diseases.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=33773\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sirius Therapeutics Partners with CRISPR Therapeutics to Develop SRSD107 for Thrombosis\" \/>\n<meta property=\"og:description\" content=\"Sino-US biotech Sirius Therapeutics has entered into a partnership with Swiss\u2013American biotech CRISPR Therapeutics (NASDAQ: CRSP) to develop and commercialize SRSD107, a Factor XI (FXI)-targeted Factor siRNA therapy for the treatment of thrombosis and thromboembolic diseases.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=33773\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-20T17:21:34+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-20T17:21:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2004-2.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33773#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33773\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sirius Therapeutics Partners with CRISPR Therapeutics to Develop SRSD107 for Thrombosis\",\"datePublished\":\"2025-05-20T17:21:34+00:00\",\"dateModified\":\"2025-05-20T17:21:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33773\"},\"wordCount\":218,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33773#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2004-2.webp\",\"keywords\":[\"CRISPR Therapeutics\",\"NASDAQ: CRSP\",\"RNAi \\\/ ASO\",\"Sirius Therapeutics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33773#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33773\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=33773\",\"name\":\"Sirius Therapeutics Partners with CRISPR Therapeutics to Develop SRSD107 for Thrombosis - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33773#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33773#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2004-2.webp\",\"datePublished\":\"2025-05-20T17:21:34+00:00\",\"dateModified\":\"2025-05-20T17:21:35+00:00\",\"description\":\"Sino-US biotech Sirius Therapeutics has entered into a partnership with Swiss\u2013American biotech CRISPR Therapeutics (NASDAQ: CRSP) to develop and commercialize SRSD107, a Factor XI (FXI)-targeted Factor siRNA therapy for the treatment of thrombosis and thromboembolic diseases.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33773#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=33773\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33773#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2004-2.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2004-2.webp\",\"width\":1080,\"height\":608,\"caption\":\"Sirius Therapeutics Partners with CRISPR Therapeutics to Develop SRSD107 for Thrombosis\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=33773#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sirius Therapeutics Partners with CRISPR Therapeutics to Develop SRSD107 for Thrombosis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sirius Therapeutics Partners with CRISPR Therapeutics to Develop SRSD107 for Thrombosis - Insight, China's Pharmaceutical Industry","description":"Sino-US biotech Sirius Therapeutics has entered into a partnership with Swiss\u2013American biotech CRISPR Therapeutics (NASDAQ: CRSP) to develop and commercialize SRSD107, a Factor XI (FXI)-targeted Factor siRNA therapy for the treatment of thrombosis and thromboembolic diseases.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=33773","og_locale":"en_US","og_type":"article","og_title":"Sirius Therapeutics Partners with CRISPR Therapeutics to Develop SRSD107 for Thrombosis","og_description":"Sino-US biotech Sirius Therapeutics has entered into a partnership with Swiss\u2013American biotech CRISPR Therapeutics (NASDAQ: CRSP) to develop and commercialize SRSD107, a Factor XI (FXI)-targeted Factor siRNA therapy for the treatment of thrombosis and thromboembolic diseases.","og_url":"https:\/\/flcube.com\/?p=33773","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-05-20T17:21:34+00:00","article_modified_time":"2025-05-20T17:21:35+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2004-2.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=33773#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=33773"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sirius Therapeutics Partners with CRISPR Therapeutics to Develop SRSD107 for Thrombosis","datePublished":"2025-05-20T17:21:34+00:00","dateModified":"2025-05-20T17:21:35+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=33773"},"wordCount":218,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=33773#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2004-2.webp","keywords":["CRISPR Therapeutics","NASDAQ: CRSP","RNAi \/ ASO","Sirius Therapeutics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=33773#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=33773","url":"https:\/\/flcube.com\/?p=33773","name":"Sirius Therapeutics Partners with CRISPR Therapeutics to Develop SRSD107 for Thrombosis - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=33773#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=33773#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2004-2.webp","datePublished":"2025-05-20T17:21:34+00:00","dateModified":"2025-05-20T17:21:35+00:00","description":"Sino-US biotech Sirius Therapeutics has entered into a partnership with Swiss\u2013American biotech CRISPR Therapeutics (NASDAQ: CRSP) to develop and commercialize SRSD107, a Factor XI (FXI)-targeted Factor siRNA therapy for the treatment of thrombosis and thromboembolic diseases.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=33773#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=33773"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=33773#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2004-2.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2004-2.webp","width":1080,"height":608,"caption":"Sirius Therapeutics Partners with CRISPR Therapeutics to Develop SRSD107 for Thrombosis"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=33773#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sirius Therapeutics Partners with CRISPR Therapeutics to Develop SRSD107 for Thrombosis"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2004-2.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33773","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=33773"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33773\/revisions"}],"predecessor-version":[{"id":33775,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/33773\/revisions\/33775"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/33774"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=33773"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=33773"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=33773"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}